On October 22nd, Digital Precision Medical (DPM) announced the completion of the A+ round of financing, which is the second financing obtained in the past six months. The total amount of the two rounds of financing is nearly 100 million yuan. The investors include the state-owned new enterprise operating investment fund and gold. Ke Jun Chuang Capital and Zi Niu Fund.
Founded in July 2016, Beijing Digital Precision Medical Technology Co., Ltd. is a company specializing in fluorescent molecular navigation technology. According to digital precision medical treatment , after obtaining two rounds of financing of nearly 100 million yuan, Digital Precision Medical will further develop molecular imaging surgical navigation products, speed up product certification registration, enhance sales and technical support team strength, and accelerate product marketization.
Preoperative real-time, non-radiative precise positioning of tumors
The latest global cancer data report published by WHO's International Agency for Research on Cancer (IARC) has revealed that the high incidence of cancer has become the number one obstacle to human life expectancy. China's cancer morbidity and mortality have been higher than the global average. . How to improve the success rate of cancer surgery, reduce surgical trauma and avoid accidents will be of great significance for cancer treatment.
At present, in conventional surgical resection of tumors, conventional imaging techniques such as CT, PET, MRI, etc. can be used to obtain preoperative anatomical structure information, which is mainly used for imaging tumors above 5 mm. In surgery, doctors can only rely on eyesight and hand touch to determine the location and size of the tumor. Whether the tumor is clean or not depends mainly on the surgeon's experience.
In response to this pain point, the near-infrared fluorescent molecular imaging surgical navigation device independently developed by Digital Precision Medical, combined with a fluorescent tracer currently available on the market, can clearly mark the tumor with near-infrared fluorescence during surgery and needs to be retained. The boundaries of normal tissues guide the physician to remove the tumor intact and retain normal tissue as much as possible. At the same time, due to the extremely high sensitivity of the near-infrared fluorescent molecular imaging surgical navigation device, a tiny tumor of 1 mm size can be found in the operation, and the surgical recurrence and micrometastases are avoided to cause postoperative tumor recurrence.
In the pre-laboratory stage, digital precision medical products have been successfully verified in the clinical research of 301 hospitals, Peking University People, Tiantan Hospital and other top three hospitals, and successfully achieved intraoperative imaging of tumors in liver cancer, lung cancer and glioma.
At present, three products have been developed: fluorescent molecular imager (super-eye), near-infrared fluorescence imaging system (Intelligent Eye), and endoscopic fluorescence imaging system (Goggles). The three core products currently mainly use surgery as the main use scene. Targeting diseases include breast cancer, liver cancer, stomach cancer, lung cancer, colorectal cancer, and esophageal cancer.
Wang Li, CEO of Digital Precision Medical, said that the product is currently undergoing approval for registration and has entered the green channel for special approval of national innovative medical devices.
Core technology to make up for the domestic market gap
Digital precision medical technology said that the core technology molecular image is the first in China, and its products will also fill the gap in the domestic market and have significant clinical value. At present, its core technology has won the National Science and Technology Progress Award and the National Technology Invention Award, the Geneva International Invention Exhibition Gold Award, the International Invention Fair Gold Award and the World Intellectual Property Organization Best Invention Award. It has the first international molecular imaging in-situ navigation technology. US patent.
It is reported that compared with similar products abroad, digital precision medical products are specially designed for tumors in hardware and algorithms, and have sensitive real-time imaging capabilities, while other products are located in lymphatic imaging and blood flow imaging, which cannot be obtained at design time. Maximum energy near-infrared fluorescence excitation and most efficient near-infrared emission. For example, in the intraoperative tumor development of lung cancer, digital precision medical products can achieve high-contrast imaging, and the resolution is higher than the competition, while other products are difficult to visualize. The relevant results have been published in the European Journal of Authoritative Cardiothoracic Surgery.
In addition, in terms of clinical application value, the product can also perform quantitative algorithm analysis of fluorescence intensity by collecting the core parameters of the hardware device (excitation light energy, excitation light efficiency, optical path transmission efficiency, and conversion efficiency). Quantitative analysis of malignant discrimination, metastatic characteristics, malignant grading, etc.
It is understood that the digital precision medical research and development team is based on the Key Laboratory of Molecular Imaging of the Chinese Academy of Sciences, covering research and development talents in information technology, biomedicine, clinical medicine, etc. There are 1 academicians of the Chinese Academy of Sciences, IEEE, IAMBE, AIMBE, SPIE. 1 person from Fellow, IAPR, OSA, 2 from the National Science and Technology Ministry, 1 from the National Science and Technology Commission, 1 from the Outstanding Youth Science Fund of the National Fund Committee, 1 from the National Youth League Foundation for Excellence in Science, and the Ministry of Education One special professor, one national outstanding science and technology worker, and one person from the Chinese Academy of Sciences “Hundred Talents Program†and so on.
For the future development, Digital Precision Medical said that it will continue to transfer the relevant artificial technical achievements such as artificial intelligence technology and tumor-targeted tracer in the Key Laboratory of Molecular Imaging of the Chinese Academy of Sciences, and drive the development of the company through independent research and development technology.
Flood Light Camera,Cctv Flood Light Camera,2Mp 3Mp Flood Light Camera,Waterproof Flood Light Camera
Shenzhen Zuomi Technology Co., Ltd. , https://www.zuomicamera.com